April 3, 2019Open Access

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Key Points

Key points are not available for this paper at this time.

Abstract

Pembrolizumab monotherapy demonstrated durable antitumor activity and manageable safety in patients with advanced cervical cancer. On the basis of these results, the US Food and Drug Administration granted accelerated approval of pembrolizumab for patients with advanced PD-L1-positive cervical cancer who experienced progression during or after chemotherapy.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Chung et al. (Wed,) studied this question.

synapsesocial.com/papers/69dbdb2664ccad2978835cb1 https://doi.org/https://doi.org/10.1200/jco.18.01265

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade2002 · 3,194 citations
2Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.1985 · 406 citations
3Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence2020 · 1,189 citations
4Targeted Gene Delivery Therapies for Cervical Cancer2020 · 61 citations
5American Society of Clinical Oncology 2012 Annual Meeting2012 · 55 citations

Demander à l'IA

Bookmark

View Full Paper